News and Press Releases
TREMFYA (guselkumab) receives positive CHMP opinion for treatment of patients with moderately to severely active Crohn’s Disease
Recommendation based on the findings from the Phase 3 studies (GALAXI programme and GRAVITI) in Crohn’s disease 28 March 2025 -- Beerse, Belgium -- Johnson & Johnson today announced that...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 28, 2025
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Following recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophils Approval marks the first new treatment...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: March 28, 2025
WCG ClinSphere Total Feasibility Releases Self-Serve Capabilities that Optimize Clinical Trial Site Selection
27 March 2025 -- North Carolina, US -- WCG, a global leader in providing solutions that measurably improve and accelerate clinical research, today announced the launch of WCG ClinSphere™ Total Feasibility's...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 27, 2025
Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata
Unique siRNA platform, developed with Nobel Prize Laureate Craig Mello, offers potential for treating multiple dermatology indications ALY-101 is formulated as an intradermal injectable for the treatment of Alopecia Areata...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 27, 2025
100 Northern Avenue Boston Massachusetts 02210, United States
Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC 25
Cleerly to Present Late-Breaking Findings and Participate in Key ACC 25 Sessions 27 March 2025 -- Illinois, US -- Cleerly, the leader in cardiovascular AI imaging, announces its participation in...
Category: Clinical Trials, Other, Pharmaceutical
Posted: March 27, 2025
RYBREVANT (amivantamab) plus LAZCLUZE (lazertinib) demonstrates significant overall survival benefit in patients with EGFR-mutated advanced non-small cell lung cancer versus osimertinib
Median overall survival not yet reached with a projected improvement of more than one year versus osimertinib 26 March 2025 -- Beerse, Belgium -- Janssen-Cilag International NV, a Johnson &...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: March 26, 2025
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
Ryvu Therapeutics to Present Preclinical Data on Synthetic Lethality at the 2025 AACR Annual Meeting
KRAS-specific synthetic lethal targets identified through Ryvu's ONCO Prime platform show promising potential for new therapeutic options for colorectal cancer (CRC) patients RVU305, a potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor,...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 26, 2025
R&D Center for Innovative Drugs Leona Henryka Sternbacha 2 30-394 Kraków, Poland
Industry Leaders Address Future of Oncology Drugs and Biotech Funding at AAPS National Biotechnology Conference
Registration Now Open 26 March 2025 -- Virginia, US -- AAPS is excited to announce the opening and closing plenary speakers for the 2025 National Biotechnology Conference (NBC), taking place...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 26, 2025
2107 Wilson Blvd #200 Arlington, VA 22201
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
25 March 2025 -- Massachusetts, US, and Gosselies, Belgium -- iTeos Therapeutics, Inc, a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025
H&T Presspart Launches Vytal®: Innovative snap-fit closure solution for advanced therapeutics
25 March 2025 – Marsberg, Germany – H&T Presspart (a division of the Heitkamp & Thumann Group), a leading developer and manufacturer of drug delivery components and devices for the...
Category: Drug Delivery, Manufacturing and Packing
Posted: March 25, 2025
Presspart Manufacturing Ltd. Whitebirk Industrial Estate Blackburn, Lancashire BB1 5RF, England
STERILINE’S ADVANCED FILLING INNOVATIONS EXHIBITED AT INTERPHEX 2025
Fully flexible servo platform filling machine presented at the trade show 25 March 2025 – New York City, US – Steriline, a well-established European manufacturer of highly specialized robotic filling...
Category: Manufacturing and Packing
Posted: March 25, 2025
Central Research Laboratories Launches Single-Use Gamma Bags for Biopharma and Life Sciences Applications
25 March 2025 -- Minnesota, US -- Central Research Laboratories (CRL), a global leader in the remote-handling industry, is launching Single-Use Gamma Bags that have been designed to undergo gamma-sterilization...
Category: Biotechnology, Logistics, Other, Pharmaceutical
Posted: March 25, 2025
ELRIG Announces Prof Rory Johnson and Dr Shalini Andersson as Keynote Speakers at Therapeutic Oligonucleotides 2025
Therapeutic Oligonucleotides 2025: Drugging the Undruggable takes place at AstraZeneca in Gothenburg, Sweden from 14–15 May 25 March 2025 -- Cambridge, UK -- ELRIG, a not-for-profit, volunteer-led organisation for the drug...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025
ELRIG (UK) Ltd. Salisbury House, Station Road, Cambridge, CB1 2LA, UK
SGLT2 HYPE – a guideline-relevant, clinical trial aiming to establish SGLT2 inhibitors as a new standard in hypertension therapy, ultimately addressing one of the leading causes of premature mortality in Germany and Europe
25 March 2025 -- Lübeck, Germany -- On January 1, 2025, the European research project SGLT2 HYPE (SGLT2 inhibition for cardiovascular reduction in HYPErtension) was officially launched, receiving €6.99 million...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025
Tolebrutinib regulatory submission accepted for priority review in the US for patients with multiple sclerosis
If approved, tolebrutinib would be the first and only brain-penetrant BTK inhibitor to both treat non-relapsing secondary progressive multiple sclerosis (MS) and slow disability accumulation independent of relapse activity Tolebrutinib...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 25, 2025
